Skip to contentE
Editas Medicine, Inc.
E
EDITEditas Medicine, Inc. Q1 2020 · 10-Q
Revenue$5.72M$5.72M+176.6% vs Q1 2019 Net Income-$37.72M-$37.72MN/M vs Q1 2019 EPS Diluted-$0.69-$0.69N/M vs Q1 2019 Operating Income-$46,616,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
Free Cash Flowderived-$56,238,000N/M Margins · derivedOperating margin-814.5%+696.4 pt vs Q1 2019
Net margin-659.2%+754.5 pt vs Q1 2019
ended Mar 31, 2020 · filed May 8, 2020 · 38 d after period end